NERVGEN PHARMA CORPNERVGEN PHARMA CORPNERVGEN PHARMA CORP

NERVGEN PHARMA CORP

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪157.49 M‬CAD
−0.37CAD
‪−22.38 M‬CAD
0.00CAD
‪54.03 M‬
Beta (1Y)
−0.40

About NERVGEN PHARMA CORP


CEO
Michael Kelly
Headquarters
Vancouver
Founded
2017
FIGI
BBG00MMMWFG2
NervGen Pharma Corp. operates as a clinical stage biotech company. It provides development of treatment that enables the nervous system to repair itself following damage, whether due to injury or disease. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of NGEN is 2.36 CAD — it has decreased by −1.75% in the past 24 hours. Watch NERVGEN PHARMA CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSXV exchange NERVGEN PHARMA CORP stocks are traded under the ticker NGEN.
NGEN stock has fallen by −17.65% compared to the previous week, the month change is a −6.67% fall, over the last year NERVGEN PHARMA CORP has showed a 21.03% increase.
We've gathered analysts' opinions on NERVGEN PHARMA CORP future price: according to them, NGEN price has a max estimate of 4.00 CAD and a min estimate of 4.00 CAD. Watch NGEN chart and read a more detailed NERVGEN PHARMA CORP stock forecast: see what analysts think of NERVGEN PHARMA CORP and suggest that you do with its stocks.
NGEN reached its all-time high on Feb 5, 2024 with the price of 3.98 CAD, and its all-time low was 0.80 CAD and was reached on Mar 25, 2020. View more price dynamics on NGEN chart.
See other stocks reaching their highest and lowest prices.
NGEN stock is 7.93% volatile and has beta coefficient of −0.40. Track NERVGEN PHARMA CORP stock price on the chart and check out the list of the most volatile stocks — is NERVGEN PHARMA CORP there?
Today NERVGEN PHARMA CORP has the market capitalization of ‪157.49 M‬, it has increased by 2.75% over the last week.
Yes, you can track NERVGEN PHARMA CORP financials in yearly and quarterly reports right on TradingView.
NERVGEN PHARMA CORP is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
NGEN earnings for the last quarter are −0.07 CAD per share, whereas the estimation was −0.07 CAD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.10 CAD per share. See more details about NERVGEN PHARMA CORP earnings.
NGEN net income for the last quarter is ‪−5.23 M‬ CAD, while the quarter before that showed ‪−7.83 M‬ CAD of net income which accounts for 33.22% change. Track more NERVGEN PHARMA CORP financial stats to get the full picture.
No, NGEN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NERVGEN PHARMA CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NERVGEN PHARMA CORP technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NERVGEN PHARMA CORP stock shows the neutral signal. See more of NERVGEN PHARMA CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.